🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 09062X103
- Market Cap
- Large Cap
- Previous Symbol
- BGEN (changed 11/13/2003)
- Previous Name
- Biogen Idec, Inc.
Business: Biogen, Inc. discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS).
Notes: February 1, 2017-- Biogen Inc. (NASDAQ: BIIB) today announced the completion of the separation of its global hemophilia business. The new company, known as Bioverativ, is an independent, publicly traded global biotechnology company focused on hemophilia and other rare blood disorders. Bioverativ common stock will begin regular way trading on Thursday, February 2, 2017, under the symbol BIVV on the NASDAQ Global Select Market.
Company Contact
- CEO
- Christopher A. Viehbacher
- CFO
- Michael McDonnell
- Headquarters
- 225 Binney Street, Cambridge, MA 02142
- Phone
- 781-464-2000 · Toll-Free 877-420-2442
- Fax
- 866-302-9723
- Investor Relations
- Mike Hencke · 781-464-2442 · IR@biogen.com